NK cell function in HIV-1 infection

Current HIV Research

Volumn 6, Issue 5, 2008, Pages 433-440

  de Maria, Andrea ^a,b,c   Moretta, Lorenzo ^c,d  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d G GASLINI INSTITUTE   (Italy)

Author keywords

Dendritic cells; HIV 1; Natural cytotoxicity receptor; NK cell

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE; CYTOKINE; DENDRITIC CELL VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN; IMMUNOLOGICAL ADJUVANT; NATURAL KILLER CELL RECEPTOR;

ADAPTIVE IMMUNITY; ADJUVANT THERAPY; ANTIGEN SPECIFICITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CELL DAMAGE; CELL FUNCTION; CELL PROTECTION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; DISEASE CONTROL; DISEASE COURSE; DOWN REGULATION; DRUG RESEARCH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; IMMUNOREGULATION; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; INNATE IMMUNITY; KAPOSI SARCOMA; LYMPHOCYTE SUBPOPULATION; LYMPHOMA; NATURAL KILLER CELL; NONHUMAN; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TARGET CELL; TUMOR IMMUNITY; UPREGULATION; VACCINE PRODUCTION; VIRUS CELL INTERACTION; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALS; HIV INFECTIONS; HIV-1; HUMANS; KILLER CELLS, NATURAL;

EID: 53849132718     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016208785861221     Document Type: Review

References (100)

1. Pantaleo G, Fauci AS. Immunopathogenesis of HIV infection. Annu Rev Microbiol 1996; 50(1): 825-54.
2. Cai Q, Huang XL, Rappocciolo G, Rinaldo CR, Jr. Natural killer cell responses in homosexual men with early HIV infection. J Acquir Immune Defic Syndr 1990; 3(7): 669-76.
3. Poli G, Introna M, Zanaboni F, et al. Natural killer cells in intravenous drug abusers with lymphadenopathy syndrome. Clin Exp Immunol 1985; 62(1):128-35.
4. Hu PF, Hultin LE, Hultin P, et al. Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16+CD56+ cells and expansion of a population of CD16dimCD56- cells with low lytic activity. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10(3): 331-40.
5. Vuillier F, Bianco NE, Montagnier L, Dighiero G. Selective depletion of low-density CD8+, CD 16+ lymphocytes during HIV infection. AIDS Res Hum Retroviruses 1988; 4(2): 121-9.
6. Bukowski JF, Woda BA, Hahn S, Okumura K, Welsh RM. Natural killer cell depletion enhances virus synthesis and virus-induced hepatitis in vivo. J Immunol 1983; 131(3): 1531-8.
7. Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med 1989; 320(26): 1731-5.
8. Lopez C, Kirkpatrick D, Read SE, et al. Correlation between low natural killing of fibroblasts infected with herpes simplex virus type 1 and susceptibility to herpesvirus infections. J Infect Dis 1983; 147(6): 1030-5.
9. Arase H, Lanier LL. Virus-driven evolution of natural killer cell receptors. Microbes Infect 2002; 4(15.): 1505-12.
10. Bottino C, Castriconi R, Moretta L, Moretta A. Cellular ligands of activating NK receptors. Trends Immunol 2005; 26(4): 221-6.
11. Lanier LL. Natural killer cells: roundup. Immunol Rev 2006; 214: 5-8.
12. Lodoen MB, Lanier LL. Viral modulation of NK cell immunity. Nature reviews 2005; 3(1): 59-69.
13. Moretta L, Biassoni R, Bottino C, et al. Human NK cells and their receptors. Microbes Infect 2002; 4(15): 1539-44.
14. Moretta L, Ferlazzo G, Bottino C, et al. Effector and regulatory events during natural killer-dendritic cell interactions. Immunol Rev 2006; 214: 219-28.
15. Moretta L, Moretta A. Killer immunoglobulin-like receptors. Curr Opin Immunol 2004; 16(5): 626-33.
16. Moretta L, Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J 2004; 23(2): 255-9.
17. Kawasaki A, Shinkai Y, Kuwana Y, et al. Perforin, a pore-forming protein detectable by monoclonal antibodies, is a functional marker for killer cells. Int Immunol 1990; 2(7): 677-94.
18. Braud VM, Allan DS, O'Callaghan CA, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998; 391(6669): 795-9.
19. Colonna M, Navarro F, Bellon T, et al. A common inhibitory receptor for major histocompatibility complex class I molecules on human lympboid and myelomanocytic cells. J Exp Med 1997; 186(11): 1809-18.
20. Roy S, Barnes PF, Garg A, Wu S, Cosman D, Vankayalapati R. NK cells lyse T regulatory cells that expand in response to an intracellular pathogen. J Immurnol 2008; 180(3): 1729-36.
21. Moretta A, Bottino C, Vitale M, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001; 19: 197-223.
22. Shibuya K, Shirakawa J, Kameyama T, et al. CD226 (DNAM-1) is involved in lymphocyte function-associated antigen 1 costimulatory signal for naive T cell differentiation and proliferation. J Exp Med 2003; 198(12): 1829-39.
23. Bottino C, Castriconi R, Pende D, et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 2003; 198(4): 557-67.
24. Sivori S, Parolini S, Falco M, et al. 2B4 functions as a co-receptor in human NK cell activation. Eur J Immunol 2000; 30(3): 787-93.
25. Bottino C, Falco, K Parolini S, et al. NTB-A [correction of GNTB-A] a novel SH2D1A-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus-infected B cells in X-Iinked lymphoproliferative disease. J Exp Med 2001; 194(3): 235-46.
26. Vitale M, Falco M, Castriconi R, et al. Identification of NKp80, a novel triggering molecule expressed by human NK cells. Eur J Immunol. 2001; 31(1): 233-42.
27. Welte S, Kuttruff S, Waldhauer I, Steinle A. Mutual activation of natural killer cells and monocytes mediated by NKp80-AICL interaction. Nat Immunol 2006; 7(12): 1334-42.
28. Le Gall S, Erdtmann L, Benichou S, et al. Nef interacts with the mu subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules. Immunity 1998; 8(4): 483-95.
29. Ward JP, Bonaparte MI, Barker E. HLA-C and HLA-E reduce antibody-dependent natural killer cell-mediated cytotoxicity of HIV-infected primary T cell blasts. AIDS (London, England) 2004; 18(13):1769-79.
30. Cohen GB, Gandhi RT, Davis DM, et al. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 1999; 10(6): 661-71.
31. Swann SA, Williams M, Story CK Bobbitt KF, Fleis R, Collins KL. HIV-1 Nef blocks transport of MHC class I molecules to the cell surface via a PI 3-kinase-dependent pathway. Virology 2001; 282(2): 267-77.
32. Koenig S, Conley AJ, Brewah YA, et al. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat Med 1995; 1(4): 330-6.
33. McMichael AJ, Phillips RE. Escape of human immunodeficiency virus from immune control. Annu Rev Immunol 1997; 15: 271-96.
34. De Maria A, Ferraris A, Guastella M, et al. Expression of HLA class I-specific inhibitory natural killer cell receptors in HIV-specific cytolytic T lymphocytes: impairment of specific cytolytic functions. Proc Natl Acad Sci USA 1997; 94(19): 10285-8.
35. De Maria A, Fogli M, Costa P, et al. The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). Eur J Immunol 2003; 33(9): 2410-8.
36. Fogli M, Costa P, Murdaca G, et al. Significant NK cell activation associated with decreased cytolytic firriction in peripheral blood of HIV-1-infected patients. Eur J Immunol 2004; 34(8): 2313-21.
37. Vitale M, Bottino C, Sivori S, et al. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Mcd 1998; 187(12): 2065-72.
38. Pantaleo G, Koenig S, Baseler M, Lane HC, Fauci AS. Defective clonogenic potential of CD8+ T lymphocytes in patients with AIDS. Expansion in vivo of a nonclonogenic CD3+CD8+DR+ CD25-T cell population. J Immunol 1990; 144(5): 1696-704.
39. Pantaleo G, Maria AD, Koenig S, et al. CD8+ T lymphocytes of patients with AIDS maintain normal broad cytolytic function despite the loss of human immunodeficiency virus-specific cytotoxicity. Proc Natl Acad Sci USA; 87(12): 4818-22.
40. Mavilio D, Lombardo G, Benjamin J, et al. Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected virernic individuals. Proc Natl Acad Sci USA 2005; 102(8): 2886-91.
41. Mela CM, Burton CT, Imami N, et al. Switch from inhibitory to activating NKG2 receptor expression in HIV-1 infection: lack of reversion with highly active antiretroviral therapy. AIDS (London, England) 2005; 19(16): 1761-9.
42. Guma M, Angulo A, Vilches C, Gomez-Lozano N, Malats N, Lopez-Botet M. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 2004; 104(12): 3664-71.
43. Guma M, Budt M, Saez A, et al. Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirtis-infected fibroblasts. Blood 2006; 107(9): 3624-31.
44. Alter G, Teigen N, Davis BT, et al. Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. Blood 2005; 106(10): 3366-9.
45. Blazevic V, Sahgal N, Kessler HA, Landay AL, Shearer GM. T cell responses to recall antigens, alloantigen, and mitogen of HIV-infected patients receiving long-term combined antiretroviral therapy. AIDS Res Hum Retroviruses 2000; 16(17): 1887-93.
46. Crowe SM, Carlin JB, Stewart KI, Lucas CR, Hoy JF. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. J Acquir Immune Defic Syndr 1991; 4(8): 770-6.
47. Clifford GM, Polesel J, Rickenbacli M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97(6): 425-32.
48. Maurer T, Ponte M, Leslie K. HIV-associated Kaposi's sarcoma with a high CD4 count and a low viral load. N Engl J Med 2007; 357(13): 1352-3.
49. Costello RT, Sivori S, Marcenaro E, et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 2002; 99(10): 3661-7.
50. Moretta A, Marcenaro E, Parolini S, Ferlazzo G, Moretta L. NK cells at the interface between innate and adaptive immunity. Cell Death Differ 2008; 15(2): 226-33.
51. Hart OM, Athie-Morales V, O'Connor GM, Gardiner CM. TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production. J Immunol 2005; 175(3): 1636-42.
52. Girart MV, Fuertes MB, Domaica CI, Rossi LE, Zwirner NW. Engagement of TLR3, TLR7, and NKG2D regulate IFN-gamma secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12. J Immunol 2007; 179(6): 3472-9.
53. Sivori S, Falco M, Della Chiesa M, et al. CpG and double-stranded RNA trigger human NK cells by Toll-like receptors induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc Natl Acad Sci USA 2004; 101(27): 10116-21.
54. Ferlazzo G, Pack M, Thomas D, et al. Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc Natl Acad Sci USA 2004; 101(47):16606-11.
55. Vitale M, Della Chiesa M, Carlomagno S, et al. NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood 2005; 106(2): 566-71.
56. Pende D, Castriconi R, Romagnani P, et al. Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction. Blood 2006; 107(5): 2030-6.
57. Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Munz C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 2002; 195(3): 343-51.
58. Lucas M, Schachterle W, Oberle K, Aichele P, Diefenbach A. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 2007; 26(4): 503-17.
59. Ferlazzo G, Morandi B, D'Agostino A, et al. The interaction between NK cells and dendritic cells in bacterial infections results in rapid induction of NK cell activation and in the lysis of uninfected dendritic cells. Eur J Immunol 2003; 33(2): 306-13.
60. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21: 685-711.
61. Carbonneil C, Donkova-Petrini V, Aouba A, Weiss L. Defective dendritic cell function in HIV-infected patients receiving effective highly active antiretroviral therapy: neutralization of IL-10 production and depletion of CD4+CD25+ T cells restore high levels of HIV-specific CD4+ T cell responses induced by dendritic cells generated in the presence of IFN-{alpha}. J Immunol 2004; 172(12.):7832-40.
62. Donaghy H, Gazzard B, Gotch F, Patterson S. Dysfunction and infection of freshly isolated blood myeloid and plasmacytoid dendritic cells in patients infected with HIV-1. Blood 2003; 101(11): 4505-11.
63. Krathwohl MD, Schacker TW, Anderson JL. Abnormal presence of semimature dendritic cells that induce regulatory T cells in HIV-infected subjects. J Infect Dis 2006; 193(4): 494-504.
64. Pacanowski J, Develioglu L, Kamga I, et al. Early plasmacytoid dendritic cell changes predict plasma HIV load rebound during primary infection. J Infect Dis 2004; 190(10):1889-92.
65. Mavilio D, Lombardo G, Kinter A, et al. Characterization of the defective interaction between a subset of natural killer cells and dendritic cells in HIV-1 infection. J Exp Med 2006; 203(10): 2339-50.
66. Fauriat C, Moretta A, Olive D, Costello RT. Defective killing of dendritic cells by autologous natural killer cells from acute myeloid leukemia patients. Blood 2005; 106(6): 2186-8.
67. Gerosa F, Gobbi A, Zorzi P, et al. The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. J Immunol 2005; 174(2): 727-34.
68. Ito T, Kanzler H, Duramad O, Cao W, Liu YJ. Specialization, kinetics, and repertoire of type 1 interferon responses by human plasmacytoid predendritic cells. Blood 2006; 107(6): 2423-31.
69. Reis e Sousa C. Toll-like receptors and dendritic cells: for whom the bug tolls. Semin Immunol 2004; 16(1): 27-34.
70. Yrlid U, Milling SW, Miller JL, Cartland S, Jenkins CD, MacPherson GG. Regulation of intestinal dendritic cell migration and activation by plasmacytoid dendritic cells, TNF-alpha and type 1 IFNs after feeding a TLR7/8 ligand. J Immunol 2006; 176(9): 5205-12.
71. Alter G, Suscovich TJ, Teigen N, et al. Single-stranded RNA derived from HIV-1 serves as a potent activator of NK cells. J Immunol 2007; 178(12): 7658-66.
72. Beignon AS, McKenna K, Skoberne M, et al. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest 2005; 115(11): 3265-75.
73. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004; 303(5663): 1529-31.
74. Jiang W, Lederman MM, Salkowitz JR, Rodriguez B, Harding CV, Sieg SF. Impaired monocyte maturation in response to CpG oligodeoxynucleotide is related to viral RNA levels in human immunodeficiency virus disease and is at least partially mediated by deficiencies in alpha/beta interferon responsiveness and production. J Virol; 79(7): 4109-19.
75. Chehimi J, Azzoni L, Farabaugh M, et al. Baseline viral load and immune activation determine the extent of reconstitution of innate immune effectors in HIV-1-infected subjects undergoing antiretroviral treatment. J Immunol 2007; 179(4): 2642-50.
76. Portales P, Reynes J, Pinet V, et al. Interferon-alpha restores HIV-induced alteration of natural killer cell perform expression in vivo. AIDS (London, England) 2003; 17(4): 495-504.
77. Robbins SH, Bessou G, Cornillon A, et al. Natural killer cells promote early CD8 T cell responses against cytomegalovirus. PLoS Pathogens 2007; 3(8): e123.
78. Warfield KL, Perkins JG, Swenson DL, et al. Role of natural killer cells in innate protection against lethal ebola virus infection. J Exp Med 2004; 200(2): 169-79.
79. Vankayalapati R, Klucar P, Wizel B, et al. NK cells regulate CD8+ T cell effector function in response to an intracellular pathogen. J Immunol 2004; 172(1): 130-7.
80. Mela CM, Steel A, Lindsay J, Gazzard BG, Gotch FM, Goodier MR. Depletion of natural killer cells in the colonic lamina propria of viraemic HIV-1-infected individuals. AIDS (London, England) 2007; 21(16): 2177-82.
81. Vankayalapati R, Wizel B, Weis SE, et al. The NKp46 receptor contributes to NK cell lysis of mononuclear phagocytes infected with an intracellular bacterium. J Immunol 2002; 168(7): 3451-7.
82. Vieillard V, Strominger JL, Debre P. NK cytotoxicity against CD4+ T cells during HIV-1 infection: a gp41 peptide induces the expression of an NKp44 ligand. Proc Natl Acad Sci USA 2005; 102(31): 10981-6.
83. Ward J, Bonaparte M, Sacks J, et al. HIV modulates the expression of ligands important in triggering natural killer cell cytotoxic responses on infected primary T-cell blasts. Blood 2007; 110(4): 1207-14.
84. Quaranta MG, Napolitano A, Sanchez M, Giordani L, Mattioli B, Viora M. HIV-1 Nef impairs the dynamic of DC/NK crosstalk: different outcome of CD56(dim) and CD56(bright) NK cell subsets. FASEB J 2007; 21(10): 2323-34.
85. Pantaleo G, Menzo S, Vaccarezza M, et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995; 332(4): 209-16.
86. Cao Y, Qin L, Zhang L, Safrit J, Ho DD. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995; 332(4): 201-8.
87. Migueles SA, Sabbaghian MS, Shupert WL, et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci USA 2000; 97(6): 2709-14.
88. Betts MR, Nason MC, West SM, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006; 107(12): 4781-9.
89. Martin MP, Gao X, Lee J-H, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002; 31(4): 429-34.
90. Alter G, Martin MP, Teigen N, et al. Differential natural killer cell mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med 2007; 204(12): 3027-36.
91. Navis M, Schellens I, van Baarle D, et al. Viral replication capacity as a correlate of HLA B57/B5801-associated nonprogressive HIV-1 infection. J Immunol 2007; 179(5): 3133-43.
92. Heeney JL, Dalgleish AG, Weiss RA. Origins of HIV and the evolution of resistance to AIDS. Science 2006; 313(5786): 462-6.
93. Rutjens E, Mazza S, Biassoni R, et al. Differential NKp30 inducibility in chimpanzee NK cells and conserved NK cell phenotype and function in long-term HIV-1-infected animals. J Immunol 2007; 178(3): 1702-12.
94. Fleury S, Rizzardi GP, Chapuis A, et al. Long-term kinetics of T cell production in HIV-infected subjects treated with highly active and retroviral therapy. Proc Natl Acad Sci USA 2000; 97(10): 5393-8.
95. Almeida M, Cordero M, Almeida J, Orfao A. Persistent abnormalities in peripheral blood dendritic cells and monocytes from HIV-1-positive patients after 1 year of antiretroviral therapy. J Acquir Immune Defic Syndr 2006; 41(4): 405-15.
96. Gruber A, Chalmers AS, Rasmussen RA, et al. Dendritic cell-based vaccine strategy against human immunodeficiency virus clade C: skewing the immune response toward a helper T cell type 2 profile. Viral Immunol 2007; 20(1): 160-9.
97. Garcia F, Lejeune M, Climent N, et al. Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J Infect Dis 2005; 191(10):1680-5.
98. Lu W, Arraes LC, Ferreira WT, Andricu JM. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 2004; 10(12):1359-65.
99. Newton PJ, Weller IV, Williams IG, et al. Monocyte derived dendritic cells from HIV-1 infected individuals partially reconstitute CD4 T-cell responses. AIDS (London, England) 2006; 20(2): 171-80.
100. Costa P, Beltrame A, A DM. May immunization strategies that target dendritic cells really offer advantages for HIV-1? AIDS (London, England) 2006; 20(9): 1351-2.